Evgen Pharma PLC
LSE:EVG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Evgen Pharma PLC
Revenue
Evgen Pharma PLC
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evgen Pharma PLC
LSE:EVG
|
Revenue
£838k
|
CAGR 3-Years
63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Revenue
£400m
|
CAGR 3-Years
41%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Revenue
£672m
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Revenue
£168.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
27%
|
|
|
Niox Group PLC
LSE:NIOX
|
Revenue
£48.7m
|
CAGR 3-Years
16%
|
CAGR 5-Years
15%
|
CAGR 10-Years
16%
|
|
Evgen Pharma PLC
Glance View
Evgen Pharma Plc is a clinical stage drug development company, which engages in the development of pharmaceutical products and focus on cancer and neurological disease. The company is headquartered in Wilmslow, Cheshire and currently employs 8 full-time employees. The company went IPO on 2015-10-21. The firm is developing sulforaphane-based medicines focused on the treatment of cancer and inflammation. The firm's pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01 for the treatment of metastatic breast cancer and acute respiratory distress syndrome. The SFX-01 reduces the number of cancer stem cells in patient-derived breast cancer tissue in xenograft models. Its SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin.
See Also
What is Evgen Pharma PLC's Revenue?
Revenue
838k
GBP
Based on the financial report for Sep 30, 2023, Evgen Pharma PLC's Revenue amounts to 838k GBP.
What is Evgen Pharma PLC's Revenue growth rate?
Revenue CAGR 3Y
63%
The average annual Revenue growth rates for Evgen Pharma PLC have been 63% over the past three years .
